Overview
CBLL market data
Price History
CBLL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.04 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -63.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10.85 – $24.33 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $732.3M · P/B 5.24 · P/S 7.70.
Company News
CeriBell shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above estimates.Benzinga · Aug 11, 2026, 7:34 PM
Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26Benzinga · Aug 11, 2026, 3:46 PM
BTIG Reiterates Buy on CeriBell, Maintains $28 Price TargetBenzinga · Aug 11, 2026, 10:33 AM
8-K filing — Ceribell, Inc. (CBLL)SEC EDGAR · Aug 10, 2026, 8:27 PM
CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M EstBenzinga · Aug 10, 2026, 8:09 PM
CeriBell Q2 EPS $(0.51) Misses $(0.47) Estimate, Sales $28.097M Beat $27.285M EstimateBenzinga · Aug 10, 2026, 8:08 PM
CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Based Neurology Portal: Epileptiform Abnormality Detection And Artifact ReductionBenzinga · Aug 10, 2026, 11:09 AM
CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor SystemBenzinga · Aug 3, 2026, 11:23 AM
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’KeefeGlobenewswire Inc · Jul 29, 2026, 11:15 AM
CeriBell Highlights Publication Of New Research Paper, 'Point-Of-Care EEG Artificial Intelligence Measure Of Seizure Burden Associates With Clinical Outcome At Discharge'Benzinga · Jun 8, 2026, 11:15 AM